Valley Cancer Medical Center INC
Valley Cancer Medical Center INC was paid $43.81M by Medicaid between Jan 2018 and Nov 2024, across 49 billing codes. Its largest line is J1447, Injection, tbo-filgrastim, 1 microgram — 89% of everything it billed.
33Billing provider infoVALLEY CANCER MEDICAL CENTER INC
MANTECA, CA 95336
MANTECA, CA 95336
33aNPI1740648856assigned 02/03/2016
33bProvider typeSpecialist
28Total paid$43.81M
24GClaims108,407
24DCodes billed49
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Specialist providers in California
Rank by total paid#1 of 1,230
Median peer was paid$51K
This provider vs. median853×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 17,848 | $4.77M | |
| 2019 | 20,923 | $9.78M | |
| 2020 | 18,889 | $8.36M | |
| 2021 | 15,455 | $5.19M | |
| 2022 | 12,301 | $5.37M | |
| 2023 | 12,626 | $5.26M | |
| 2024incomplete | 10,365 | $5.08M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| J1447 | Injection, tbo-filgrastim, 1 microgram | 89% | 14,944 | 1,547 | $39.00M |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 1.5% | 2,720 | 1,490 | $665K |
| J9271 | Injection, pembrolizumab, 1 mg | 1.4% | 44 | 36 | $595K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 1.1% | 5,988 | 2,811 | $470K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 1.1% | 4,662 | 2,301 | $463K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 17,791 | 2,315 | $389K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 4,495 | 2,115 | $311K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 17,257 | 2,907 | $264K |
| 96367 | <1% | 3,986 | 1,999 | $259K | |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | <1% | 5,090 | 4,773 | $224K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | <1% | 6,121 | 5,327 | $169K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 2,762 | 1,368 | $152K |
37 more codes
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 2,584 | $144K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 2,804 | $105K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 5,692 | $100K |
| 96417 | <1% | 1,106 | $53K | |
| 77014 | <1% | 707 | $46K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 839 | $45K |
| 99205 | Prolong outpt/office vis | <1% | 465 | $45K |
| J2780 | Injection, ranitidine hydrochloride, 25 mg | <1% | 1,760 | $39K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 409 | $31K |
| 96523 | <1% | 1,055 | $28K | |
| 77334 | <1% | 247 | $24K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 248 | $23K |
| 77336 | <1% | 366 | $21K | |
| J0897 | Injection, denosumab, 1 mg | <1% | 12 | $21K |
| 77301 | <1% | 24 | $15K | |
| J2916 | Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | <1% | 197 | $14K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,994 | $12K |
| 77427 | <1% | 80 | $10K | |
| 77290 | <1% | 109 | $9K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 101 | $8K |
| 36000 | <1% | 254 | $8K | |
| 77263 | <1% | 31 | $8K | |
| 77300 | <1% | 109 | $6K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 228 | $6K |
| 77338 | <1% | 24 | $5K | |
| S0164 | Injection, pantoprazole sodium, 40 mg | <1% | 428 | $5K |
| J0640 | Injection, leucovorin calcium, per 50 mg | <1% | 54 | $5K |
| 96415 | <1% | 114 | $4K | |
| J9190 | Injection, fluorouracil, 500 mg | <1% | 67 | $3K |
| 96411 | <1% | 82 | $2K | |
| A4215 | Needle, sterile, any size, each | <1% | 107 | $2K |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 26 | $2K |
| 96416 | <1% | 22 | $1K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 66 | $422.39 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 37 | $410.13 |
| Q0166 | Granisetron hydrochloride, 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 24 hour dosage regimen | <1% | 36 | $151.56 |
| A4927 | Gloves, non-sterile, per 100 | <1% | 63 | $3.86 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDHALIWAL, AMARJIT (CEO/MD)
| Provider | Location | Paid |
|---|---|---|
| Valley Cancer Medical Group | Modesto, CA | $121K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.